Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Expanded_access × Hematologic Diseases × pirtobrutinib × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Interventional 5 Expanded_access 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Lymphoid 1

Conditions

Waldenstrom Macroglobulinemia 1 Syndrome 1 Lymphoma, Mantle-Cell 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Hematologic Diseases 1

Interventions

pirtobrutinib 1 Brentuximab Vedotin 1 Bone Marrow Transplantation 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05172700 2024-12-18

Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer

Eli Lilly and Company

Approved for marketing

LymphoidOther hematologic neoplasm

Hematologic Diseases, Waldenstrom Macroglobulinemia, Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡